Condition: Persistent Corneal Epithelial Defect · Sponsor: Noveome Biotherapeutics, formerly Stemnion
The primary objective is to determine the efficacy of ST266 eye drops in healing persistent epithelial defects (PED). After 8 weeks of randomized, double-blind treatment, non-healers will enter into an additional 8-week open-label ST266 treatment period. All patients will be followed for 3-months post-treatment for monitoring of safety and maintenance of re-epithelialization.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Trinity Research Group | Dothan, Alabama, United States | — |
| University of Arkansas for Medical Sciences | Little Rock, Arkansas, United States | — |
| Atlantis Eye Care | Huntington Beach, California, United States | — |
| UCLA Stein Eye Institute | Los Angeles, California, United States | — |
| Stanford | Palo Alto, California, United States | — |
| UCLA Doheny Eye Center | Pasadena, California, United States | — |
| California Eye Specialists Medical Group | Pasadena, California, United States | — |
| Bowden Eye & Associates | Jacksonville, Florida, United States | — |
| Shettle Eye Research | Largo, Florida, United States | — |
| Millennium Clinical Research, Inc | Miami, Florida, United States | — |
| MedEye Associates | Miami, Florida, United States | — |
| Cincinnati Eye Institute | Edgewood, Kentucky, United States | — |
+ 19 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05066698